New cell therapy shows potential against solid tumors with KRAS mutations

A new technology for cellular immunotherapy developed by Abramson Cancer Center researchers at Penn Medicine showed promising anti-tumor activity in the lab against hard-to-treat cancers driven by the once-considered “undruggable” KRAS mutation, including lung, colorectal, and pancreatic. The foundational technology is available for licensing through PCI.

Read the Article in Penn Today

Skip to content